Joep de Bruijne

Assistant Professor - medical

Strategic program(s):

Contact

jbruijn7@umcutrecht.nl

Pure profile

Research groups

Primary Liver Tumors research group

Research aim

To improve surveillance, diagnostics, treatment, and outcome for patients with primary liver tumors (hepatocellular carcinoma and cholangiocarcinoma) by interdisciplinary and (inter-)national collaborative research

Go to group

Recent publications

All publications

Hepatobiliary scintigraphy and liver function changes in patients with hepatocellular carcinoma treated with 166Ho-radioembolization Margot T M Reinders, Maarten J L Smits, Karel van Erpecum, Joep de Bruijne, Rutger C G Bruijnen, Dave Sprengers, Rob de Man, Erik Vegt, Jan N M IJzermans, Marnix G E H Lam, Arthur J A T Braat
EJNMMI Research, 2025, vol. 15

Conventional versus Hepatic Arteriography and C-Arm CT-Guided Ablation of Liver Tumors (HepACAGA) Niek Wijnen, Rutger C G Bruijnen, Evert-Jan P A Vonken, Hugo W A M de Jong, Joep de Bruijne, Guus M Bol, Jeroen Hagendoorn, Martijn P W Intven, Maarten L J Smits
Cancers, 2024, vol. 16

Medicatie review na TIPS-plaatsing Maartje van de Meeberg, S van Meer, Laureen A Lammers, Bart Takkenberg, Joep de Bruijne
MAGMA, 2024, vol. 2024, p.147-149

Holmium-166 radioembolisation dosimetry in HCC Margot T.M. Reinders, Arthur J.A.T. Braat, Karel J. van Erpecum, Joep de Bruijne, Rutger C.G. Bruijnen, Dave Sprengers, Rob de Man, Erik Vegt, Jan N.M. IJzermans, Sjoerd G. Elias, Marnix G.E.H. Lam, Maarten L.J. Smits
European Journal of Nuclear Medicine and Molecular Imaging, 2024, vol. 52, p.993-1003

Hepatic Arteriography and C-Arm CT-Guided Ablation (HepACAGA) to Improve Tumor Visualization, Navigation and Margin Confirmation in Percutaneous Liver Tumor Ablation Maarten L.J. Smits, Rutger C.G. Bruijnen, Philip Tetteroo, Evert jan P.A. Vonken, Martijn R. Meijerink, Jeroen Hagendoorn, Joep de Bruijne, Warner Prevoo
Cardiovascular and Interventional Radiology, 2023, vol. 46, p.1365-1374

Miravirsen dosing in chronic hepatitis C patients results in decreased microRNA-122 levels without affecting other microRNAs in plasma M. H. Van Der Ree, A. J. Van Der Meer, A. C. Van Nuenen, J. De Bruijne, S. Ottosen, H. L. Janssen, N. A. Kootstra, H. W. Reesink
Alimentary Pharmacology and Therapeutics, 2016, vol. 43, p.102-113